Solid Biosciences Inc. (SLDB)

Nasdaq Biotechnology Diagnostics SIC: 2836
D
Pipeline Grade

Financial Position (from SEC Filings)

$298.4M
Cash & Equivalents
$47.2M
Quarterly Burn Rate
19 mo
Est. Cash Runway
$691M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT03368742 Microdystrophin Gene Transfer Study in Adolescents and Children With DMD PHASE2 Active Not Recruiting 12

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for SLDB.

SEC EDGAR Filings

All SEC filings for Solid Biosciences Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.